Vincerx Pharma Stock Forecast, Price & News

-0.18 (-0.94 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $19.06
50-Day Range
MA: $20.31
52-Week Range
Now: $19.06
Volume28,643 shs
Average Volume99,351 shs
Market Capitalization$156.39 million
P/E RatioN/A
Dividend YieldN/A
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in clinical trials. Its drug candidates are in development for the treatment of solid tumors, leukemia, B-cell malignancies, lymphomas, and myelodysplastic syndrome. Vincerx Pharma, Inc. is based in Palo Alto, California.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:VINC
Phone650 800 6676
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$156.39 million
Next Earnings DateN/A
OptionableNot Optionable


No headlines for this company have been tracked by


Overall MarketRank

1.00 out of 5 stars

Medical Sector

1065th out of 2,010 stocks

Biotechnology Industry

46th out of 143 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.18 (-0.94 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VINC News and Ratings via Email

Sign-up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Vincerx Pharma (NASDAQ:VINC) Frequently Asked Questions

Is Vincerx Pharma a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vincerx Pharma stock.
View analyst ratings for Vincerx Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Vincerx Pharma?

Wall Street analysts have given Vincerx Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vincerx Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Vincerx Pharma's key executives?

Vincerx Pharma's management team includes the following people:
  • Dr. Ahmed M. Hamdy, Founder, Chairman & CEO (Age 56, Pay $622.05k)
  • Dr. Raquel E. Izumi, Founder, Pres, COO, Sec. & Director (Age 51, Pay $652.84k)
  • Mr. Alexander A. Seelenberger M.B.A., MBA, Chief Financial Officer (Age 42, Pay $405.46k)
  • Mr. Stuart Hwang Ph.D., Chief Bus. Officer & Founder
  • Mr. Tom C. Thomas, Founder, Gen. Counsel & Chief Legal Officer
  • Dr. John C. Byrd M.D., Founder
  • Dr. Xiaoming Zhang Ph.D., Chief Technical Officer (Age 57)
  • Dr. Hans-Georg Lerchen Ph.D., Chief Scientific Officer
  • Dr. Hermes Garban M.D., Ph.D., Chief Medical Officer
  • Dr. David Nganele M.B.A., Ph.D., Head of Early Devel.

Who are some of Vincerx Pharma's key competitors?

What is Vincerx Pharma's stock symbol?

Vincerx Pharma trades on the NASDAQ under the ticker symbol "VINC."

How do I buy shares of Vincerx Pharma?

Shares of VINC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vincerx Pharma's stock price today?

One share of VINC stock can currently be purchased for approximately $19.06.

How much money does Vincerx Pharma make?

Vincerx Pharma has a market capitalization of $156.39 million.

How many employees does Vincerx Pharma have?

Vincerx Pharma employs 28 workers across the globe.

What is Vincerx Pharma's official website?

The official website for Vincerx Pharma is

How can I contact Vincerx Pharma?

The company can be reached via phone at 650 800 6676.

This page was last updated on 4/10/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.